Apthera Copyright  |   Site Map  |  
 
 
 
  Apthera  
 
Breast cancer

NeuVax™ (E75) for Breast Cancer

Apthera's peptide-based cancer immunotherapy, NeuVax, is designed to prevent recurrence in early-stage breast cancer patients. Learn more >

 
Apthera News

August 5, 2008

Apthera and TGen Drug Development Services (TD2) Sign Master Services Agreement

June 2, 2008

Apthera’s NeuVax™ Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients

Events & Updates

April 29, 2008

ASCO
Updated Calendar of Events:
NEW: Apthera to present at the BIO International Convention 2008 in San Diego

 

Clinical research
Research

Apthera research is focused on discovering and developing tumor-associated peptides that can be used to make effective cancer immunotherapies.
Learn more >

Product Development

Through clinical trials, Apthera is developing new immunotherapies that target HER2-expressing cancers.
Learn more >